Why is Glenmark Pharma falling/rising?

As of 23-Jul, Glenmark Pharmaceuticals Ltd. is currently priced at 2,140.40, reflecting a decrease of 13.85 points or 0.64%. The stock has been underperforming recently, having fallen consecutively for the last four days, resulting in a total decline of 3.87% during this period. Despite this short-term downturn, the stock has shown strong performance over the longer term, with a remarkable 50.99% increase over the past year and a staggering 471.46% rise over the last three years. The company has demonstrated a solid ability to service debt, evidenced by a low Debt to EBITDA ratio of 1.00 times, and has reported positive results for the last four consecutive quarters, including a significant growth in PAT. Additionally, high institutional holdings at 37.8% suggest a strong confidence from knowledgeable investors.
In the broader market context, Glenmark's recent performance contrasts with the Sensex, which has seen a slight increase of 0.11% over the past week. While Glenmark has underperformed its sector by 1.15% today, it has outpaced the benchmark with a 26.58% gain over the past month compared to the Sensex's 1.01%. The rising investor participation, indicated by a 34.27% increase in delivery volume, suggests that there is still interest in the stock despite its recent declines. Overall, while Glenmark Pharmaceuticals has faced short-term challenges, its strong fundamentals and historical performance indicate potential resilience in the face of market fluctuations.